Medication Guide App

Label Changes for:

Isentress (raltegravir potassium) 400 mg tablets

November 2009

Changes have been made to the ADVERSE REACTIONS and PATIENT PACKAGE INSERT sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2009

ADVERSE REACTIONS

Postmarketing Experience
  • Blood and Lymphatic System Disorders: thrombocytopenia

PATIENT PACKAGE INSERT

What are the possible side effects of Isentress?
  • Other: low blood platelet count
Hide
(web1)